Wu-Qi Qiu1, Ju-Fang Shi2, Lan-Wei Guo3, A-Yan Mao1, Hui-Yao Huang2, Guang-Yu Hu1, Pei Dong1, Fang-Zhou Bai2, Xiao-Ling Yan1, Xian-Zhen Liao4, Guo-Xiang Liu5, Ya-Na Bai6, Jian-Song Ren2, Xiao-Jie Sun7, Xin-Yu Zhu2, Jin-Yi Zhou7, Ji-Yong Gong8, Lin Zhu9, Ling Mai3, Ling-Bing Du10, Qi Zhou11, Xiao-Jing Xing12, Bing-Bing Song13, Yu-Qin Liu14, Pei-An Lou15, Xiao-Hua Sun16, Shou-Ling Wu17, Rong Cao18, Xiao Qi19, Li Lan20, Ying Ren21, Kai Zhang2, Jie He2, Chunfeng Qu2, Min Dai2. 1. Public Health Information Research Office, Institute of Medical Information, Chinese Academy of Medical Sciences, Beijing, P. R. China. 2. Program Office for Cancer Screening in Urban China, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Cancer Center of China, No. 17 Panjiayuannanli, Chaoyang District, Beijing, P. R. China. 3. Department of Cancer Epidemiology, Henan Office for Cancer Control and Research, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, No. 127 Dongming Road, Zhengzhou, Henan, P. R. China. 4. Department of Human Resources, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, P. R. China. 5. Department of Health Economics, School of Health Management, Harbin Medical University, Harbin, Heilongjiang, P. R. China. 6. Institute of Epidemiology and Health Statistics, Lanzhou University, Lanzhou, Gansu, P. R. China. 7. Center for Health Management and Policy, Key Lab of Health Economics and Policy, Shandong University, Jinan, Shandong, P. R. China. 8. Science and Education Department of Public Health Division, Shandong Tumor Hospital, Jinan, Shandong, P. R. China. 9. Teaching and Research Department, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, Xinjiang, P. R. China. 10. Zhejiang Office for Cancer Control and Research, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, P. R. China. 11. Chongqing Office for Cancer Control and Research, Chongqing Cancer Hospital, Chongqing, P. R. China. 12. Liaoning Office for Cancer Control and Research, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, P. R. China. 13. Heilongjiang Office for Cancer Control and Research, Affiliated Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, P. R. China. 14. Cancer Epidemiology Research Center, Gansu Provincial Cancer Hospital, Lanzhou, Gansu, P. R. China. 15. Department of Control and Prevention of Chronic Non-Communicable Diseases, Xuzhou Center for Disease Control and Prevention, Xuzhou 221006, Jiangsu, P. R. China. 16. Ningbo Clinical Cancer Prevention Guidance Center, Ningbo No. 2 Hospital, Ningbo, Zhejiang, P. R.C Shandong, P. R. China. 17. Health Department of Kailuan Group, Kailuan General Hospital, Tangshan, Hebei, P. R. China. 18. Department of Health Policy and Economic Research, Guangdong Provincial Institute of Public Health, Guangzhou, Guangdong, P. R. China. 19. Department of Occupational Medicine, Tangshan People's Hospital, Tangshan, Hebei, P. R. China. 20. Institute of Chronic Disease Prevention and Control, Harbin Center for Disease Control and Prevention, Harbin, Heilongjiang, P. R. China. 21. Urban Office of Cancer Early Detection and Treatment, Tieling Central Hospital, Tieling, Liaoning, P. R. China.
Abstract
OBJECTIVE: This study aims to understand the medical expenditure for liver cancer during 2002-2011 in urban areas of China. MATERIALS AND METHODS: This is a retrospective study. Based on a stratified cluster sampling method, a medical expenditure survey collected basic personal information from related medical records. Two-tailed independent sample t-test, variance analysis, and Student-Newman-Keuls Tests were used in cost analysis for the corresponding data types. RESULTS: A total of 12,342 liver cancer patients were included in the analysis. Overall average medical expenditure per case for liver cancer diagnosis and treatment in China has increased from ¥21, 950 to ¥40, 386 over the study period. For each liver cancer patient diagnosed between 2009 and 2011, the average expenditures were 29,332 CNY for stage I, 35,754 CNY for stage II, 34,288 CNY for stage III, and 30,275 CNY for stage IV diseases (P < 0.001). Pharmaceuticals accounted for the biggest part of the medical expenditure and it rose from 48.01% to 52.96% during these ten years, and the share of nursing fee expenses was the lowest (around 1%). Over the entire 10-year data period, the per capita expenditure of the east region (32,983 CNY) was higher than that of the west region (26,219 CNY) and slightly higher than the central region (31,018 CNY, P < 0.001). DISCUSSION: As a major cancer in China, liver cancer accounts for a large portion of health economic burden and its medical expenditure is heavy for families. Early diagnosis and treatment for liver cancer will save medical expenditure. CONCLUSION: The economic burden of liver cancer is high in China and related medical expenditure has increased.
OBJECTIVE: This study aims to understand the medical expenditure for liver cancer during 2002-2011 in urban areas of China. MATERIALS AND METHODS: This is a retrospective study. Based on a stratified cluster sampling method, a medical expenditure survey collected basic personal information from related medical records. Two-tailed independent sample t-test, variance analysis, and Student-Newman-Keuls Tests were used in cost analysis for the corresponding data types. RESULTS: A total of 12,342 liver cancer patients were included in the analysis. Overall average medical expenditure per case for liver cancer diagnosis and treatment in China has increased from ¥21, 950 to ¥40, 386 over the study period. For each liver cancer patient diagnosed between 2009 and 2011, the average expenditures were 29,332 CNY for stage I, 35,754 CNY for stage II, 34,288 CNY for stage III, and 30,275 CNY for stage IV diseases (P < 0.001). Pharmaceuticals accounted for the biggest part of the medical expenditure and it rose from 48.01% to 52.96% during these ten years, and the share of nursing fee expenses was the lowest (around 1%). Over the entire 10-year data period, the per capita expenditure of the east region (32,983 CNY) was higher than that of the west region (26,219 CNY) and slightly higher than the central region (31,018 CNY, P < 0.001). DISCUSSION: As a major cancer in China, liver cancer accounts for a large portion of health economic burden and its medical expenditure is heavy for families. Early diagnosis and treatment for liver cancer will save medical expenditure. CONCLUSION: The economic burden of liver cancer is high in China and related medical expenditure has increased.
Entities:
Keywords:
Cost analysis; liver cancer; medical care costs; retrospective survey
Authors: Haike Lei; Lin Lei; Jufang Shi; Yongzhong Wu; Ling Liang; Huiyao Huang; Mei He; Fangzhou Bai; Maomao Cao; Hui Qiu; Yuting Wang; Chengcheng Liu; Jia Du; Hong Wang; Yan Zhang; Mengdi Cao; Ji Peng; Ni Li; Chunfeng Qu; Min Dai; Wanqing Chen; Jie He Journal: Chin J Cancer Res Date: 2020-08 Impact factor: 4.026